In addition to Jefferies, Dexcom also received a Buy from Canaccord Genuity’s William Plovanic in a report issued today. However, on the same day, Barclays maintained a Sell rating on Dexcom (NASDAQ: ...

DexCom (NASDAQ: DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Dexcom reports 13% Q4 revenue growth to $1.26B, beating analyst expectations despite mixed analyst ratings and competitive pressures.

DexCom has a lower P/E than the aggregate P/E of 56.86 of the Health Care Equipment & Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also ...

DexCom Inc. DXCM shares were mostly flat in Thursday's extended trading after the company released its fourth-quarter earnings report. Here's a look at the details in the report. Watch the price DXCM ...

In a report released today, Patrick Wood from Morgan Stanley maintained a Buy rating on Dexcom, with a price target of $75.00. According to TipRanks, Wood is an analyst with an average return of -1.2% ...

The average one-year price target for DexCom (XTRA:DC4) has been revised to 77,50 € / share. This is a decrease of 12.36% from the prior estimate of 88,43 € dated November 9, 2025. The price target is ...

Investing.com - DexCom (NASDAQ: DXCM) reported fourth quarter EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $1.26B versus the consensus estimate of ...